ASPHO Webinars Connect Learners to the Latest in Pediatric Hematology/Oncology Clinical Treatment, Best Practices, and Professional Development

Speakers:
Karen Chao, MD (Moderator)
Stanford Medicine Children's Health

Lauren Vasta, MD (Moderator)
US Army Walter Reed Medical Center

J. Nathan Yarnall, MD, MPH
Children's Hospital of Savannah

Eleny Romanos-Sirakis, MD
Staten Island University Hospital

Description:
Join us for an insightful webinar exploring the unique rewards and daily realities of practicing in a small pediatric hematology/oncology program. Hear firsthand from experienced providers as they walk through a "day in the life," highlighting the close-knit patient relationships, diverse clinical caseloads, and collaborative care models distinct to smaller practice settings.

Designed specifically for pediatric heme/onc fellows and staff, this session will provide valuable perspectives for those considering their future career paths or looking to understand different practice environments. Don't miss this opportunity to ask questions and discover if a smaller community program is the right fit for your clinical journey.

Learning Objectives:

1. Understand the daily operational structure and clinical workflows unique to a provider in a small-volume pediatric hematology/oncology program
2. Discuss how a smaller clinical setting influences patient-provider continuity, multidisciplinary collaboration, and the delivery of comprehensive pediatric hematologic and oncologic care
3. Evaluate the professional growth opportunities, resource management, and work-life balance considerations associated with practicing in a community-based or smaller program compared to larger academic centers

Speaker:
Tammuella Chrisentery- Singleton, MD

Program Synopsis:
This program will focus on an ultra-rare bleeding disorder, Hereditary Factor X Deficiency (HFXD). Attendees will learn more about this severe bleeding disorder, including symptoms, testing, and unique severity scale. During this session, Dr. Singleton will also discuss the burden of disease, current treatment landscape, considerations for patient management, and the role of single-factor replacement, COAGADEX, in the treatment of HFXD.

Register Here: https://app.smartsheet.com/b/form/019e177195b27ebc89b48ef8466167f4

Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

• Routine prophylaxis to reduce the frequency of bleeding episodes
• On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency

Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.

Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call Kedrion at 1-866-398-0825 or email This email address is being protected from spambots. You need JavaScript enabled to view it. .